Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Southampton spin-out scoops major healthcare prize for revolutionary liver disease treatments

14.11.2005


Southampton-based company iQur has scooped the 2005 Medical Futures Department of Health Award for Best National Healthcare Innovation for its Hepatitis C diagnostic service, that can revolutionise the cost-effectiveness of treatment for Hepatitis C. iQur, formerly named HepCgen Limited, spun out from the University of Southampton in 2003.



The Medical Futures Innovations Awards are often referred to as the ‘Oscars of Healthcare’. iQur was presented with the Award for its research into the detection, treatment and monitoring of Hepatitis C and other liver diseases at the awards ceremony in London.

Accepting the Award from supermodel Caprice, Professor William Rosenberg, iQur’s founding Chief Scientific Officer and Professor of Hepatology at the University of Southampton, said: ‘This award is testament to the importance and success of our diagnostic services. iQur is the first Southampton-based company to be recognised at this level and we achieved this as a result of our expert team and their tremendous dedication to develop better care for the increasing threat of Hepatitis C across the globe. iQur’s strategies enable therapies to be tailored to the individual patient – potentially reducing treatment time and side effects, saving the NHS millions of pounds in clinical and pharmaceutical expenses. Following this innovation will be our simple blood test to reduce the requirement of serial liver biopsy across Europe, then the introduction of better treatment for Hepatitis C’


Speaking on behalf of the University of Southampton, Dr Tony Raven, Director of its Centre for Enterprise and Innovation (CEI) said, ‘Winning this very prestigious and hotly contested award is a fitting tribute to the work of Professor Rosenberg and his scientific team at iQur Limited.’ Earlier this year two other University of Southampton spin-out companies, SPI Lasers and OHM, were finalists in the Royal Academy of Engineering’s prestigious MacRobert Award, which recognises the successful development of innovative ideas in engineering. ‘The recognition our spin-out companies are receiving from these awards reflects the real commercial significance of our research and technology,’ he added.

As well as recognition within the medical community, iQur has also attracted positive attention from the investment community, and has successfully raised further investment of £2.6 million in an oversubscribed funding round. The funding will be used to establish the company’s Diagnostic Services business, the iQur® Speciality Pharmaceutical distribution division and grow various therapeutic in-licensing agreements.

Commenting on the investment and Award, David Norwood, Board Director and CEO of IP2IPO, a major investor in iQur, said: ‘UK universities are originators of some of the best novel intellectual property in the world, and the University of Southampton and the progress of the iQur team to deliver innovation to the global problem of liver disease, specifically, Hepatitis C, is an inspiration to all our portfolio companies, and fully reflective of our mission. iQur’s progress is underlined by the success of this financing round.’

In addition, iQur has also extended its focus and pipeline beyond Hepatitis C into liver fibrosis and secured a licensing deal with The University of Southampton. Liver fibrosis is the result of fatty liver disease, obesity, hepatitis, alcoholic liver disease and others. Over the last 20 years, the University has achieved an international reputation for its study of the pathology of fibrosis, cirrhosis, then cancer of the liver.

Commenting on these significant announcements, Paul Colford, CEO, said: ‘I am delighted that iQur’s ground breaking research into the diagnosis, treatment and monitoring of major liver diseases has been recognised on such a wide range of fronts, by the Department of Health, the investment community and the University, and underlines our company’s goal to become THE liver disease company.’

Sarah Watts | alfa
Further information:
http://www.soton.ac.uk

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>